WHO ICTRP trial
Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la…
EUCTR2010-021449-28-FR · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2010-021449-28-FR |
|---|---|
| Public title | Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde - AFORA |
| Scientific title | Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde - AFORA |
| Primary sponsor | CHRU de TOURS |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | France |
| Conditions | Polyarthrite rhumatoïde MedDRA version: 12.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis |
| Interventions | Trade Name: HUMIRA Pharmaceutical Form: Solution for injection INN or Proposed INN: ADALIMUMAB CAS Number: 331731-18-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- |
| Registration date | Sep 8, 2010 |
| Secondary IDs | PHRI10 – DM – AFORA |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: